Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B3 | P37058 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androsterone SCHEMBL10273502 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL269982 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL13175783 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Epiandrosterone SCHEMBL295167 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL12811704 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15426610 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL23031469 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL9940929 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL19750468 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL21114416 | 1.00 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 911 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4740024-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | The University Court Of The University of Edinburgh (GB) | 2026-05-13 | — | — | EP | claimed |
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | WASHINGTON UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| US-20250213589-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | Maximus Health, Inc. (US) | 2025-07-03 | — | — | US | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025096781-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED SKIN REGIMENS | VIBRANT HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025008638-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-01-09 | — | — | WO | claimed |
| US-20240041898-A9 | NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS | WASHINGTON UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| WO-2024023324-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2024-02-01 | — | — | WO | claimed |
| WO-2023083020-A1 | USE OF SERUM METABOLIC MARKER FOR DETECTING EGFR MUTATION AND DETECTION SYSTEM | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-05-19 | — | — | WO | claimed |
| WO-1996016680-A1 | PHOSPHOCHOLINE DRUG DERIVATIVES | AMUR RESEARCH CORP. (US) | 1996-06-06 | — | — | WO | claimed |
| WO-1995010291-A1 | METHODS FOR COLLECTION AND CRYOPRESERVATION OF HUMAN GRANULOCYTES | CELLPRO II (US) | 1995-04-20 | — | — | WO | claimed |
| US-5006517-A | Administering 3-oxo or hydroxy substituted 5-beta-androstan-17-one | PROGENICS, INC. (US) | 1991-04-09 | — | — | US | claimed |
| US-4897390-A | 3-METHYLANDROSTAN-17-ONE; CONCURRENT SUPPRESSION OF CALORIC INTAKE AND INCREASE OF CALORIC EXPENDITURE | HUMANETICS CORPORATION | 1990-01-30 | — | — | US | claimed |
| US-4722899-A | INDUCE IMMUNOLOGICAL TOLERANCE TO SECOND ANTIGEN THEN IMMUNIZING WITH FIRST ANTIGEN | Hamaoka, Toshiyuki (JP) | 1988-02-02 | — | — | US | claimed |
| US-4628052-A | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities | PEAT RAYMOND F | 1986-12-09 | — | — | US | claimed |
| EP-0149220-A2 | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones | The Jackson Laboratory (US) | 1985-07-24 | — | — | EP | claimed |
| EP-0148436-A1 | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen | The Jackson Laboratory (US) | 1985-07-17 | — | — | EP | claimed |
| US-4507289-A | Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen | PROGENICS, INC. (US) | 1985-03-26 | — | — | US | claimed |
| US-4321208-A | Preparation of directly iodinated steroid hormones and related compounds | SAHADEVAN VELAYUDHAN | 1982-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213589-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SHBG, AR, CYP19A1 | G6PD 997/4885GPBAR1 466/4885LMNA 3750/4885 |
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | ATG13, GSK3B, HSD11B1 | G6PD 1662/4885GPBAR1 623/4885LMNA 3367/4885 |
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | G6PD 1366/4885GPBAR1 650/4885LMNA 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.